Utilization of the Oncotype Dx Assay for Young Patients with Early Stage, Hormone-Receptor Positive, HER2-Negative Breast Cancer in an Integrated Health System

被引：0
|
作者：
Aller, Ashley
Darbinian, Jeanne A.
Liu, Raymond
Kuehner, Gillian
Savitz, Alison
Odele, Patience
Habel, Laurel
Vuong, Brooke
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P6-01-27
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-01-27
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer
    Sobhani, Navid
    Generali, Daniele
    Zanconati, Fabrizio
    Bortul, Marina
    Scaggiante, Bruna
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2018, 9 (08): : 172 - 179
  • [32] Molecular classification of hormone receptor-positive HER2-negative breast cancer
    Xi Jin
    Yi-Fan Zhou
    Ding Ma
    Shen Zhao
    Cai-Jin Lin
    Yi Xiao
    Tong Fu
    Cheng-Lin Liu
    Yi-Yu Chen
    Wen-Xuan Xiao
    Ya-Qing Liu
    Qing-Wang Chen
    Ying Yu
    Le-Ming Shi
    Jin-Xiu Shi
    Wei Huang
    John F. R. Robertson
    Yi-Zhou Jiang
    Zhi-Ming Shao
    Nature Genetics, 2023, 55 : 1696 - 1708
  • [33] Oncotype DX score in hormone receptor-positive/HER2-positive breast cancer: A SEER analysis.
    Qasrawi, Ayman
    Myint, Zin
    Alnimer, Yanal Mufeed
    Romond, Edward H.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] Use of Oncotype DX in systemic treatment decision making for patients with stage I and II, hormone receptor positive, HER2/neu-negative breast cancer.
    Zhu, Xiaofu
    Dent, Susan Faye
    Paquet, Lise
    Zhang, Tinghua
    Graham, Nadine A.
    Song, Xinni
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Utilization of oncotype DX in node-negative, ER-positive breast cancer patients
    Patel, H.
    Hook, K.
    Kaplan, C.
    Davidson, R.
    DeMichele, A.
    Fox, K. R.
    Domchek, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Everolimus or ribociclib in patients with HER2-negative, hormone-receptor positive metastatic breast cancer and circulating tumor cells: Results from DETECT IVa
    Fehm, T. N.
    Schochter, F.
    Rack, B.
    Wimberger, P.
    Banys-Paluchowski, M.
    Neubauer, H.
    Wiesmueller, L.
    Meier-Stiegen, F.
    Fasching, P. A.
    Blohmer, J-U.
    Hartkopf, A. D.
    Heublein, S.
    Huober, J.
    Riethdorf, S.
    Pantel, K.
    Schneeweiss, A.
    Friedl, T. W. P.
    Mueller, V.
    Janni, W.
    ANNALS OF ONCOLOGY, 2024, 35 : S367 - S367
  • [37] Patterns of chemotherapy receipt among patients with hormone receptor-positive, HER2-negative breast cancer
    Linnea T. Olsson
    Alina M. Hamilton
    Sarah C. Van Alsten
    Jennifer L. Lund
    Til Stürmer
    Hazel B. Nichols
    Katherine E. Reeder-Hayes
    Melissa A. Troester
    Breast Cancer Research and Treatment, 2024, 204 : 107 - 116
  • [38] Clinical Importance of estrogen reactivity in Hormone Receptor Positive HER2-Negative Breast Cancer
    Takeshita, Takashi
    Iwase, Hirotaka
    Takabe, Kazuaki
    CANCER SCIENCE, 2023, 114 : 597 - 597
  • [39] Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer
    Garrigos, Laia
    Camacho, Daniela
    Perez-Garcia, Jose Manuel
    Llombart-Cussac, Antonio
    Cortes, Javier
    Antonarelli, Gabriele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (10) : 949 - 958
  • [40] Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
    Lopez-Tarruella, Sara
    Jerez, Yolanda
    Marquez-Rodas, Ivan
    Echavarria, Isabel
    Martin, Miguel
    FUTURE ONCOLOGY, 2017, 13 (24) : 2137 - 2149
12345